NeoMatrix Therapeutics, Inc.

NeoMatrix Therapeutics, Inc. (NMT) is a clinical-stage biotechnology company headquartered in the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York. The company was founded by Richard A. Clark, M.D., a Professor of Dermatology, Biomedical Engineering, and Medicine at Stony Brook University, following years of research into why certain wounds fail to heal. That work led to the discovery of cell-survival peptides found in the extracellular matrix that are absent in nonhealing wounds and burns. NeoMatrix's therapeutic approach centers on bioactive peptides designed to prevent injury progression — the continued tissue destruction that follows an initial burn — thereby rescuing tissue and speeding healing. Its two lead candidates are NMT-cP12 and NMT-cNP8. In preclinical porcine burn models, intravenous NMT-cP12 administered 2–8 hours post-burn and intravenous NMT-cNP8 administered 8–24 hours post-burn shortened healing time. NMT-cNP8 has also been identified as an anti-microbial peptide under development for topical use, with potential applications in battlefield conditions as well as civilian settings. The company's development has been supported by the US Army, which began funding NMT-cP12 in 2012 and NMT-cNP8 in 2015 and has continued supporting both programs. Both peptides have completed intravenous Phase 1 clinical trials, and an intravenous Phase 2a trial of NMT-cP12 was slated to launch in May 2025. NeoMatrix positions its peptides as potentially improving quality of life and clinical outcomes for severe burn patients by shortening healing time and reducing scarring, and it is exploring broader uses beyond burns. As a privately held, clinical-stage company, NeoMatrix operates in the biotechnology sector with a focus on severe burns and tissue injury. Its stated mission is to reimagine tissue injury therapies through innovations in healing.

NeoMatrix Therapeutics, Inc. (NMT) was founded by Richard A. Clark, M.D., Professor of Dermatology, Biomedical Engineering, and Medicine at Stony Brook University. The company's origins lie in years of investigation by Dr. Clark and Dr. Lin into why wounds fail to heal. That research identified cell-survival peptides in the extracellular matrix that are absent in nonhealing wounds and burns. These peptides, NMT-cP12 and NMT-cNP8, were found to promote tissue cell survival and growth under harsh culture conditions that mimic unfavorable wound conditions. In preclinical work using a porcine burn model, the team found that intravenous NMT-cP12 administered 2–8 hours post-burn and intravenous NMT-cNP8 administered 8–24 hours post-burn shortened healing time. NMT-cNP8 was additionally characterized as an anti-microbial peptide, opening a path toward topical development. The US Army began funding development of NMT-cP12 in 2012 and NMT-cNP8 in 2015, and has continued supporting both peptides since. Both candidates completed intravenous Phase 1 clinical trials. An intravenous Phase 2a trial of NMT-cP12 was scheduled to launch in May 2025. The company is also exploring cNP8 topical therapy for battlefield conditions as well as civilian settings. NeoMatrix is headquartered in the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York. As a clinical-stage company, it remains focused on developing bioactive peptides that prevent injury progression, rescue tissue, and speed healing, with an initial emphasis on severe burns.

• 2025

  Intravenous Phase 2a clinical trial of NMT-cP12 slated to launch in May 2025.

• 2015

  US Army begins funding development of NMT-cNP8.

• 2012

  US Army begins funding development of NMT-cP12.

Clinical-stage biotech focused on bioactive peptides that prevent injury progression and speed healing in severe burns and tissue injury, with US Army-backed development.

• NMT-cP12

  Bioactive cell-survival peptide; intravenous lead candidate for severe burns; completed Phase 1 and entering Phase 2a in May 2025.

• NMT-cNP8

  Bioactive anti-microbial peptide; completed intravenous Phase 1; under development for topical use in battlefield and civilian settings.

1. 1NeoMatrix Therapeutics: Rethinking Tissue Injuryneomatrixtx.com
2. 2NeoMatrix Therapeutics | Our Storyneomatrixtx.com
3. 3NeoMatrix Therapeutics | Our Storyneomatrixtx.com
4. 4NeoMatrix Therapeutics (United States) — Wikidatawikidata.org